FDA Issues 29 Product-Specific Guidance’s to Advance Generic Drug Development in 2026

FDA

By VETTAPHARMA reporter – Derek Roche: The US Food and Drug Administration (FDA) has published a new batch of 29 draft product-specific guidances (PSGs) to support generic drug development and the preparation of abbreviated new drug applications (ANDAs). The latest release brings the total number of PSGs published by the agency during calendar year 2026 to 268.

The latest batch includes 15 new and 14 revised guidances. Of these, 24 address products without approved ANDAs, including nine complex products. Overall, 11 guidances relate to complex products, comprising four new and seven revised PSGs.

PSGs provide recommendations on developing generic drug products and generating evidence to demonstrate therapeutic equivalence to specific reference listed drugs. According to the FDA, these guidances are intended to facilitate generic drug development, streamline ANDA assessments and support broader access to generic medicines.

The newly published guidances cover several recently approved medicines, including orforglipron calcium (Foundayo; NDA 220934), nerandomilast (Jascayd; NDA 218764) and zongertinib (Hernexeos; NDA 219042).

Orforglipron is an oral, once-daily, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management. Nerandomilast is a selective phosphodiesterase-4B (PDE4B) inhibitor for idiopathic pulmonary fibrosis, while zongertinib is an oral tyrosine kinase inhibitor approved for first-line expansion treatment of HER2-mutant non-small cell lung cancer.

The batch also includes revised guidances informed by research funded through the Generic Drug User Fee Amendments (GDUFA) programme. The revised product-specific guidance for betaxolol hydrochloride ophthalmic drops/suspension (BETOPTIC S; NDA 019845) adds an in vitro bioequivalence option based on collaborative research involving computational modelling.

Another revised guidance, covering trifarotene topical cream (AKLIEF; NDA 211527), introduces an alternative characterisation-based bioequivalence approach.

The FDA stated that the draft PSGs will describe its current thinking and recommendations on developing generic products therapeutically equivalent to their respective reference listed drugs once finalised. The agency will consider comments submitted to the public docket before issuing final guidance.

Alongside the new batch, the FDA updated its Upcoming Product-Specific Guidances for Generic Drug Product Development webpage. The updated resource lists new and revised guidances under development, including planned revision categories and brief descriptions of proposed changes.

The action also supports the objectives of the FDA’s Drug Competition Action Plan and US Executive Order 14273, titled Lowering Drug Prices by Once Again Putting Americans First, which seeks to accelerate generic drug development and approvals.

Quick FAQs

1. What is the disease condition?

The FDA’s latest PSG batch covers multiple therapeutic areas rather than one disease. Examples include obesity, idiopathic pulmonary fibrosis and HER2-mutant non-small cell lung cancer.

2. What is the study/trial?

This is not a clinical trial. It is an FDA regulatory guidance update covering the development of generic drug products and the evidence required for abbreviated new drug applications.

3. What are product-specific guidances (PSGs)?

PSGs provide FDA recommendations on developing generic versions of specific reference listed drugs and generating evidence to demonstrate therapeutic equivalence.

4. How many product-specific guidances did the FDA publish in this batch?

The FDA published 29 draft PSGs: 15 new and 14 revised. This brings the total published during calendar year 2026 to 268.

5. Which complex generic products are covered?

The batch includes 11 guidances for complex products, comprising four new and seven revised PSGs. Examples of research-supported revisions include betaxolol hydrochloride ophthalmic drops/suspension and trifarotene topical cream.

6. What happens before the draft guidances become final?

The FDA will consider comments submitted to the public docket before finalising the PSGs. Once finalised, they will describe the agency’s current recommendations for developing therapeutically equivalent generic products.

← Back

Thank you for your response. ✨